Meghana Keshavan

Jonathan Mowens, a freelance science journalist, discusses a groundbreaking study on enabling fully paralyzed individuals to communicate through thought. Meghana Keshavan, a biotech reporter, comments on the controversial background of the scientists involved. The conversation dives into innovative communication techniques, highlighting advanced brain signaling tech for ALS patients. They also tackle the fascinating realm of non-verbal communication, emphasizing the importance of body language and the challenges of ethical implications in this revolutionary field.

Rachel Cohrs Zhang, chief Washington correspondent for STAT, talks about the recent pharmaceutical negotiations with Medicare, highlighting significant discounts and the industry's reactions. Meghana Keshavan dives into the world of psychedelics, discussing the troubling retraction of three pivotal research papers and FDA setbacks for notable therapies. They explore the ethical implications of these developments and the future of psychedelic treatments in mental health, emphasizing the implications for regulatory integrity and research credibility.

STAT colleague Meghana Keshavan dissects Lykos Therapeutics' meeting with FDA. Topics include challenges in FDA approval for psychedelic therapy, Novartis's acquisition of Morphosis, ASCO conference reflections, and FDA advisory panel vote against MDMA for PTSD.